Silexion Therapeutics Corp is moving its lead pancreatic cancer candidate, SIL204, into a mid-to-late-stage clinical trial, marking a significant milestone for the small-cap biotech. The company announced it has received clearance from Israeli regulators to initiate a Phase 2/3 study and has submitted a Clinical Trial Application in Germany through the European Union's clinical trial framework. Despite this progress, Silexion's financial position remains precarious, with only $2.4 million in cash and equivalents as of March 31, down from $6.0 million at the end of 2025.
The company reported a first-quarter net loss of $2.7 million, wider than the $1.7 million loss in the same period last year, driven by a more than doubling of research and development expenses to $1.37 million. Management has expressed "substantial doubt" about the company's ability to continue as a going concern without additional funding, according to its recent 10-Q filing. Silexion's shares closed at 26.9 cents on Tuesday, following a sharp 42% decline on May 15, reflecting investor concerns over its cash runway and financing prospects.
Clinical Progress and Strategy
SIL204 is an siRNA drug designed to silence specific KRAS mutations, which are present in approximately 90% of pancreatic cancers. The planned trial will evaluate SIL204 in combination with standard chemotherapy for locally advanced pancreatic cancer. The study will begin with a safety run-in phase involving about 18 patients, followed by a randomized phase with approximately 166 patients. CEO Ilan Hadar described this as a "defining moment" for the company, noting that SIL204 has transitioned from a preclinical asset to a clinical-stage development program.
To address its funding gap, Silexion has pursued equity-linked financing. On May 15, the company announced agreements for warrant exercises on nearly 2 million ordinary shares at a reduced exercise price of 50 cents per share, expected to generate gross proceeds of approximately $1 million before fees and expenses. CFO Mirit Horenshtein Hadar stated that the company is "evaluating financing alternatives" to support its operations and clinical trial activities.
Market and Competitive Landscape
The pancreatic cancer treatment space is becoming increasingly competitive. Revolution Medicines recently reported that its RAS-targeting drug, daraxonrasib, met primary endpoints in a Phase 3 trial for previously treated metastatic pancreatic ductal adenocarcinoma. While this addresses a different patient population, it underscores the pressure on smaller developers like Silexion to demonstrate a differentiated approach. Silexion's ability to execute its clinical plan while securing funding will be critical to its survival.
The company also faces operational challenges, including obtaining site clearances, patient recruitment, drug supply management, and simultaneous fundraising. Analysts note that these tasks are particularly daunting for a microcap biotech with limited cash reserves. Silexion's stock remains thinly traded and low-priced, which can lead to volatility and make financing more expensive. Additionally, the company must continue to comply with Nasdaq's listing requirements, including minimum shareholder equity and share price thresholds.
As Silexion moves forward with its Phase 2/3 trial, the next few months will be pivotal. The company's ability to secure additional funding and advance SIL204 through clinical development will determine whether it can overcome its current financial hurdles and establish a foothold in the competitive pancreatic cancer market.
